Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Core Insights - Ultragenyx Pharmaceutical Inc. shares are experiencing a decline following the release of data from its Phase 3 study of DTX301, a gene therapy for ornithine transcarbamylase (OTC) deficiency [1][2] Study Results - The 36-week data from the Phase 3 study of DTX301 indicated a significant 18% reduction in 24-hour plasma ammonia levels in treated patients compared to placebo [3][5] - Eight out of nine patients with elevated ammonia levels at baseline achieved normal ammonia levels during the treatment period, with 50% of DTX301-treated patients having normal baseline ammonia AUC levels [4] - Patients treated with DTX301 maintained ammonia levels in the normal range despite a mean 27% reduction in ammonia scavenger medications and a 13% increase in protein intake [5] Safety Profile - DTX301 demonstrated a well-tolerated safety profile, consistent with previous Phase 1/2 data, with mild to moderate transient hepatic reactions being the most common adverse events [6] - One serious adverse event of acute hepatitis was deemed treatment-related but resolved with steroid treatment [6] Future Outlook - The study will continue to its second primary endpoint, focusing on the reduction in treatment burden, with data expected in the first half of 2027 [7] Stock Performance - Ultragenyx shares are currently trading 3.7% below the 20-day simple moving average and 24.8% below the 100-day simple moving average, indicating bearish momentum [8] - Over the past 12 months, shares have decreased by 46.87%, nearing their 52-week lows [8] Technical Analysis - The Relative Strength Index (RSI) is at 43.32, indicating neutral territory, while the MACD shows a value of -0.5147, suggesting mixed momentum [9] Analyst Consensus - The stock carries a Buy Rating with an average price target of $71.45, although recent analyst actions have lowered targets [10]